Filing Flows › Actinium Pharmaceuticals (ATNM) › Q2 2026
Actinium Pharmaceuticals (ATNM) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 7, 2026
Actinium Pharmaceuticals (ATNM) reported revenue of $35.0M for the second quarter 2026 (Q2 2026). Operating margin was 78.8%, net earnings $27.9M (79.7% of revenue).
Actinium Pharmaceuticals, Q2 2026: revenue $35.0M, operating margin 78.8%, net earnings $27.9M, operating cash flow −$5.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $35.0M | — | — |
| Operating profit | $27.6M | — | — |
| Net earnings | $27.9M | — | — |
| Operating cash flow | −$5.2M | — | — |
What changed
Revenue was $35.0M in Q2 2026.
Operating profit was $27.6M, a 78.8% margin. Net earnings were $27.9M. The effective tax rate was 0.0%.
Operating cash flow was −$5.2M. Non-cash charges added back $432K of depreciation and amortization and $118K of share-based compensation. Working capital and other items used $33.6M. Capital expenditures of $478K exceeded it, leaving free cash flow of −$5.7M.
Questions
What was Actinium Pharmaceuticals' revenue in the second quarter 2026?
Actinium Pharmaceuticals (ATNM) reported revenue of $35.0M for the second quarter 2026 (Q2 2026).
Was Actinium Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $27.6M (78.8% of revenue) and net earnings $27.9M.